Encompass Health heads into its May 7 Q1 report with options traders making the most bullish bet of the past year.
The put/call ratio collapsed to 0.08 on May 1 — the lowest reading in 52 weeks and more than 2.5 standard deviations below its 20-day mean of 0.29. That is not cautious hedging. It is a concentrated tilt toward calls, unusual even for a stock that has run 11% over the past month to $107.48. The one-day gain alone was 7.5% on May 1, and the one-week move is nearly 5.4%. Options traders are not fading that rally — they are extending it.
Short interest does nothing to complicate the bull case. Shorts have been covering steadily, with SI % of free float falling to 2.96% from around 3.6% a month ago — a 15% decline in shares short over the period. Borrow availability is extremely loose, and cost to borrow is just 0.51%, essentially free. There is no squeeze dynamic, no borrow pressure, and nothing in the lending market to suggest a meaningful bear camp is being built ahead of the print.
The analyst community has been consistently constructive, with the consensus mean target at $141.82 — implying roughly 32% upside to the current price. The most recent data point of note was Barclays maintaining Overweight with a $153 target in February, though most of the target-raise activity happened across 2025. Bulls point to Encompass Health's growing Medicare Advantage book — now around 16.5% of the payer mix versus roughly 9% in 2018 — and a consistent track record of beating estimates (EPS surprise ranks in the 83rd percentile). Bears flag the execution risks tied to de novo facility expansion: construction costs, staffing pressures, and the drag on margins before new hospitals reach maturity. With the stock trading at 17.6x earnings and an EV/EBITDA around 10x — both multiples having expanded over the past month — there is not much room for a guidance miss.
Institutional ownership reflects a patient, long-biased holder base. T. Rowe Price added roughly 1.5 million shares through Q1, making it the most active builder among top holders. BlackRock and Vanguard together hold over 20% of the float. Insider activity in late February showed a cluster of executive sales at prices around $107–$108, near current levels — a detail worth noting, though the lot sizes were modest and routine in nature. The one more significant sale was from Treasurer Edmund Fay, who sold nearly 12,000 shares in March for $1.28 million.
The May 7 report is therefore a test of whether volume growth and MA mix gains can sustain the margin trajectory the Street has priced in — with calls already loaded and shorts largely gone, the reaction to any guidance disappointment will have few natural shock absorbers.
See the live data behind this article on ORTEX.
Open EHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
